Nrg Lu-008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
Posted Date: Apr 26, 2024
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
- Type of Study: Device
This study is being done to answer the following question: Can we help you live longer, and can we delay the time without your cancer getting worse by giving high-dose radiation therapy directly to your lung tumor – a technique called Stereotactic Body Radiation Therapy or SBRT – before the usual treatment with radiation therapy and chemotherapy? We are doing this study to find out if this approach is better or worse than the current approach for lung cancer. NRG-LU008 is a clinical study for people with non-small cell lung cancer (NSCLC) that has spread to the lymph nodes in the chest that are not able to be treated by surgery. Typically, people with NSCLC are treated with radiation therapy and chemotherapy, followed by the immune therapy drug ‘durvalumab;’ however, only approximately 33 out of 100 patients who receive this treatment plan are free of cancer at 5 years. NRG-LU008 was designed to test if adding a higher dose of radiation directly to your lung tumor using a technique called Stereotactic Body Radiation Therapy or SBRT to the usual treatment can help patients live longer and delay the time without their cancer getting worse. For more information, please visit https://www.nrgoncology.org/LU008
Criteria:
If You Over The Age Of 18 Years With Locally-Advanced Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery, You May Be Able To Participate.
Keywords:
Lung Cancer, Radiation Therapy, Non-Small Cell Lung Cancer
For More Information:
Dr. Emily Daugherty, Md
5135844073
daugheec@ucmail.uc.edu